Oriental Fortune Capital, a venture capital firm, led a $100m Series B round in Bao Pharmaceuticals, a biopharmaceutical company, with participation from Haitong Innovation and Guosheng Group-backed Sun Rock Capital. Shanghai-based recombinant protein and antibody drug specialist said that it will use the funds to drive the commercialization of core products in development and key clinical trials for new pipelines.